

Reversing Hormone Resistance: Have We Found the Golden Key?

Hope S. Rugo and Sara Keck, *University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA*

See accompanying article on page 2718

Hormone receptors are present in the majority of both early- and late-stage breast cancers, with expression found in approximately 65% to 70% of metastatic tumors. Despite the availability of a number of effective hormone therapies, resistance develops in a subset of early-stage tumors and in almost all tumors in the advanced setting. In addition, a subset of hormone receptor–positive tumors are primarily resistant to hormone therapies. The search for mechanisms to reverse resistance has focused on inhibiting pathways that are known to be upregulated in the setting of progressive disease.¹⁻³ Improvements in response and progression-free survival (PFS) that were seen with the addition of human epidermal growth factor receptor 2 (HER2)–targeted therapy to first-line aromatase inhibitors in patients with HER2–positive, hormone receptor–positive metastatic breast cancer represented the first clear indication that targeting growth factor receptor pathways could be an effective approach to reversing resistance,^{4,5} and added additional validity to preclinical models that predicted this effect.³ However, only approximately 8% to 10% of breast cancers are both HER2- and hormone receptor–positive, so the search for other approaches remains a critical research and clinical question.

Phosphatidylinositol 3-kinase (PI3K) is the most frequently altered pathway in breast cancer, with both mutations and amplifications of the encoding genes.⁶ This pathway mediates a number of critical cellular processes including cell growth, proliferation, and survival. Mammalian target of rapamycin (mTOR) is a signal transduction kinase in the PI3K pathway that exists in two multiprotein complexes, mTOR complexes 1 and 2 (mTORC1 and mTORC2; Fig 1). mTORC1 consists of mTOR that is associated with raptor (regulatory-associated protein of mTOR) and is downstream of AKT. In contrast, mTORC2 is associated with rictor (rapamycin-insensitive companion of mTOR) and phosphorylates AKT. Activation of PI3K phosphorylates AKT, which in turn phosphorylates mTORC1, which then phosphorylates its effectors, including eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and S6 kinase 1 (S6K1). 4E-BP1 plays an important role in enhancing cell proliferation, survival, and angiogenesis, and S6K1 is a key regulator of cell growth that phosphorylates ribosomal protein S6 as well as other important targets.

Activation of the PI3K pathway has been associated with resistance to hormone therapy in preclinical studies, and S6K1 directly phosphorylates the activation domain of estrogen receptors.⁷⁻⁹ A variety of studies have shown an interaction between inhibition of




Fig 1. Schematic of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Reciprocal cross-talk exists between the estrogen receptor (ER) and growth factor receptor (GFR) signaling pathways. ER can induce transcription of genes important to GFR pathways, and PI3K can phosphorylate ER to modulate this transcriptional activity. 4E-BP1, 4E-binding protein-1; E, estrogen; EGFR, epidermal growth factor receptor; eIF-4E, eukaryotic initiation factor-4E; FKBP-12, FK506-binding protein-12; HER2, human epidermal growth factor receptor 2; IGF-1R, insulin-like growth factor-1 receptor; IRS, insulin receptor substrate; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; PTEN, phosphatase and tensin homolog deleted on chromosome 10; S6, 40S ribosomal protein; S6K1, S6 kinase 1.

mTOR and restoration of hormone sensitivity, particularly when inhibitors are given in combination with hormone agents.¹⁰⁻¹² These data, along with availability of mTOR inhibitors in the clinic, increased interest in the potential of mTOR inhibition to improve response to hormonal therapies. On the basis of encouraging results from a phase II trial, 1,112 patients with hormone therapy–naïve, metastatic breast cancer were randomly assigned to letrozole or letrozole combined with the mTOR inhibitor temsirolimus.¹³ The study was closed for futility by the data monitoring committee when it became clear that the experimental arm was highly unlikely to demonstrate improvement in PFS, the primary end point, and subsequent

analysis showed no difference in response. Grade 3 toxicity was increased in the experimental arm. An unplanned subset analysis suggested benefit in the 50% of patients with exposure to previous chemotherapy, and a planned analysis suggested benefit in younger patients who are more likely to have highly proliferative and hormone-resistant disease. Toxicity was modest, with less than 3% of patients reporting grade 3 to 4 mucositis. Potential reasons for these disappointing results include an inadequate dose or schedule (temsirolimus was dosed at 30 mg a day for 5 days in a row every 14 days, and toxicity was unexpectedly low) or possible dilution of benefit in the 55% of patients without previous exposure to adjuvant hormone therapy and presumably reduced activation of resistance pathways.

Everolimus is a rapamycin analog that inhibits mTORC1 kinase through high affinity binding to FK506-binding protein-12. In addition, preclinical data suggest that prolonged exposure to rapamycin may result in inhibition of mTORC2.^{14,15} In a previous neoadjuvant trial, the combination of letrozole and everolimus improved clinical response and reduced tumor cell proliferation as measured by Ki67 compared with letrozole alone.¹⁶ Mutational analyses documented PI3K mutations in 35% of patients, with a suggestion of improved reduction in Ki67 in those with mutations in exon 9. The phase III Breast Cancer Trial of Oral Everolimus 2 (BOLERO-2) randomly assigned 724 women with hormone receptor-positive metastatic breast cancer who previously progressed on nonsteroidal aromatase inhibitors to receive exemestane and a placebo or everolimus.¹⁷ Patients who received everolimus had a significantly longer PFS (median, 6.9 months *v* 2.8 months by investigator assessment; *P* < .001), as well as an improved overall response rate. As expected, the addition of everolimus increased toxicity and particularly stomatitis (grade 3, 8% *v* 1%). Pneumonitis, although increased, was uncommon (grade 3, 3% *v* 0%). Survival data are still immature, although more deaths were seen in the placebo arm (22.6% *v* 17.3%) in a recent update with a median follow-up of 12.5 months.¹⁸

In the article that accompanies this editorial, Bachelot et al¹⁹ report the results of the Tamoxifen Plus Everolimus (TAMRAD) trial, a randomized phase II trial that tested the combination of tamoxifen with everolimus compared with tamoxifen alone in patients previously treated with aromatase inhibitors. Although this study included only 111 patients, the results are striking and even more so in the context of the recently published BOLERO-2 data. Both trials hypothesized that restricting enrollment to patients with progression in the setting of previous hormone therapy would enrich for tumors driven by the PI3K/AKT/mTOR pathways, an approach that was apparently successful. Indeed, clinical data suggest that genetic alterations in the PI3K pathway may arise late in tumor development,^{20,21} and a gene expression signature of PI3K activation was enriched in luminal B breast cancers, which tend to be less hormone responsive.²² The primary end point in TAMRAD was clinical benefit rate at 6 months, which was significantly improved in patients treated with tamoxifen and everolimus compared with those who received tamoxifen alone (61% *v* 42%). An exploratory analysis of both time to progression and overall survival demonstrated improved outcome with the addition of everolimus. Interestingly, 84% of patients enrolled onto the BOLERO-2 trial were described as having hormone-sensitive disease, which was defined as disease that had demonstrated evidence of previous response to hormone therapy; however, subset analysis failed to demonstrate any difference in efficacy on the basis of this criteria. This is in contrast to the subset

analysis in the TAMRAD trial, which suggested that the primary benefit of adding everolimus was seen in patients with hormone-sensitive disease rather than in those with primary hormone resistance. It is likely that the subsets were too small in TAMRAD to be reliable, or that BOLERO-2 was not informative in primary hormone resistance. Toxicity was similar between the two trials.

How should we use this information in clinical practice? First, it is clear that the addition of targeted agents to standard therapy often, if not always, increases toxicity of therapy as well as cost, and risk should be weighed against expected benefit in an individual patient. If well tolerated, a more than doubling of PFS certainly seems to be worthwhile. Both BOLERO-2 and TAMRAD enrolled patients whose tumors had previously progressed on noncorticosteroidal aromatase inhibitors, and whose tumors had not progressed on the hormone therapy used in each trial—exemestane or tamoxifen, respectively. A recent preclinical study²³ showed that the antitumor effects of PI3K inhibition could be reversed with exogenous estrogen, suggesting that treatment with PI3K pathway-targeted therapy alone in hormone receptor-positive disease might not be effective. Taken together, these data suggest that everolimus should be used in the clinic in combination with a secondary hormone agent in patients with hormone receptor-positive, advanced disease that progresses during or recurs after aromatase inhibitor therapy. Efficacy and toxicity did not seem to be age dependent in BOLERO-2, and TAMRAD is too small to evaluate these subsets. However, patients with significant comorbidities, or rapidly progressive disease that is associated with organ dysfunction, are probably not optimal candidates for this combination therapy. In addition, caution should be used in patients with primary hormone resistance, although there is no convincing evidence as yet to indicate that these patients should be excluded. An understanding of toxicity management, including appropriate dose reductions and delays when needed, will be critical components of safe and effective clinical use.

Future research is focusing on targeting patients with known mutations of the PI3K pathway with novel inhibitors and evaluating rational combinations of targeted biologic agents. Recent data from 217 patients with a variety of solid tumors treated in the phase I setting with PI3K/AKT/mTOR inhibitors showed higher responses in the subset who were found to have PI3K mutations compared with those with wild-type cancers.²⁴ Inhibition of mTORC1 may reduce negative feedback on growth factor receptors, including the insulin-like growth factor-1 receptor and HER3, which could potentially negate the impact of mTOR inhibition on tumor cells.²⁵ The mTOR inhibitor ridaforolimus combined with the insulin-like growth factor-1 receptor inhibitor dalotuzumab is being studied in a phase II study on the basis of encouraging phase I data,²⁶ and the HER3 antibody MM-121 is also being studied in a phase II study in combination with exemestane. A number of other approaches to reverse hormone resistance are currently being evaluated, as well as additional inhibitors of the PI3K pathway. Everolimus is also being tested in HER2-positive disease in two ongoing phase III trials after demonstrated responses in combination with chemotherapy and trastuzumab in trastuzumab-resistant disease.²⁷

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked

with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None **Consultant or Advisory**

Role: None **Stock Ownership:** None **Honoraria:** None **Research**

Funding: Hope S. Rugo, Novartis, Pfizer, Merck **Expert Testimony:**

None **Other Remuneration:** None

AUTHOR CONTRIBUTIONS

Manuscript writing: All authors

Final approval of manuscript: All authors

REFERENCES

1. Osborne CK, Shou J, Massarweh S, et al: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. *Clin Cancer Res* 11:865s-870s, 2005
2. Johnston SR: Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. *Clin Cancer Res* 12:1061s-1068s, 2006
3. Schiff R, Massarweh SA, Shou J, et al: Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: Implicated role of growth factor signaling and estrogen receptor coregulators. *Cancer Chemother Pharmacol* 56:10-20, 2005 (suppl 1)
4. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. *J Clin Oncol* 27:5538-5546, 2009
5. Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. *J Clin Oncol* 27:5529-5537, 2009
6. Miller TW, Balko JM, Arteaga CL: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. *J Clin Oncol* 29:4452-4461, 2011
7. Miller TW, Hennessey BT, González-Angulo AM, et al: Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. *J Clin Invest* 120:2406-2413, 2010
8. Massarweh S, Osborne CK, Creighton CJ, et al: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. *Cancer Res* 68:826-833, 2008
9. Kang S, Bader AG, Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. *Proc Natl Acad Sci U S A* 102:802-807, 2005
10. deGraffenried LA, Friedrichs WE, Russell DH, et al: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. *Clin Cancer Res* 10:8059-8067, 2004
11. Boulay A, Rudloff J, Ye J, et al: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. *Clin Cancer Res* 11:5319-5328, 2005
12. Sanchez CG, Ma CX, Crowder RJ, et al: Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. *Breast Cancer Res* 13:R21, 2011

13. Chow LWC, Sun Y, Jassem J, et al: Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. *Breast Cancer Res Treat* 100, 2006 (suppl 1; abstr 6091)
14. Efeyan A, Sabatini DM: mTOR and cancer: Many loops in one pathway. *Curr Opin Cell Biol* 2:169-176, 2010
15. Sarbassov DD, Ali SM, Sengupta S, et al: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. *Mol Cell* 22:159-168, 2006
16. Baselga J, Semiglazov V, van Dam P, et al: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. *J Clin Oncol* 27:2630-2637, 2009
17. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 366:520-529, 2012
18. Hortobagyi G: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. San Antonio Breast Cancer Symposium, San Antonio, TX, December 7, 2011 (abstr S3-7)
19. Bachelot T, Bourgier C, Cropet C, et al: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. *J Clin Oncol* 30:2718-2724, 2012
20. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al: PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. *Mol Cancer Ther* 10:1093-1101, 2011
21. Dupont Jensen J, Laenkhölm AV, Knoop A, et al: PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. *Clin Cancer Res* 17:667-677, 2011
22. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 98:10869-10874, 2001
23. Crowder RJ, Phommaly C, Tao Y, et al: PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. *Cancer Res* 69:3955-3962, 2009
24. Janku F, Tsimberidou AM, Garrido-Laguna I, et al: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. *Mol Cancer Ther* 10:558-565, 2011
25. O'Reilly KE, Rojo F, She QB, et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res*, 66:1500-1508, 2006
26. Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, et al: A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors. *J Clin Oncol* 28:235s, 2010 (suppl 15; abstr 3008)
27. Morrow PK, Wulf GM, Ensor J, et al: Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. *J Clin Oncol* 29:3126-3132, 2011

DOI: 10.1200/JCO.2012.42.1271; published online ahead of print at www.jco.org on July 2, 2012